Pediatric inflammatory bowel diseases in patients with genetic syndromes: A case–control multicentre SIGENP study

OBJECTIVES: To characterize the clinical phenotype and long-term outcomes of pediatric inflammatory bowel disease (IBD) in patients with genetic syndromes. METHODS: Multicenter observational case-control study using data from the Italian Society of Pediatric Gastroenterology, Hepatology, and Nutrition IBD registry. Patients diagnosed with pediatric-onset IBD (<18 years) between 2009 and 2024 were included. Syndromic cases were matched 1:2 with non-syndromic controls by gender, age at diagnosis, IBD type, and follow-up duration. Demographic, clinical, and therapeutic data were analyzed. RESULTS: Sixty-nine patients were included (23 syndromic and 46 controls). At diagnosis, syndromic patients had lower weight (-1.16 z-score, p = 0.004) and height (-1.43 z-score, p < 0.001); these differences persisted at follow-up. Diagnostic delay was longer in syndromic patients (+6.5 months, p = 0.045). Abdominal pain was less frequent at presentation (p = 0.01). Syndromic patients had more hospitalizations (IBD-related incidence rate ratio [IRR] 1.23, p = 0.033; non-IBD IRR 1.65, p < 0.001), more comorbidities (odds ratio [OR] 18.2, p < 0.001), and greater use of non-IBD medications (OR 8.17, p = 0.004). The risk of additional autoimmune diseases was higher but not statistically significant. CONCLUSIONS: Pediatric IBD patients with genetic syndromes show impaired growth and delayed diagnosis, while intestinal disease activity and treatment exposure are comparable to non-syndromic peers. The higher burden of comorbidities and hospitalizations indicates greater healthcare complexity and diagnostic challenges; early recognition and coordinated multidisciplinary care are reasonable clinical considerations, but their impact on outcomes requires prospective evaluation.

Authors

Institutions

Publication Details

Journal
Journal of Pediatric Gastroenterology and Nutrition
Published
2026-11-12
DOI
https://doi.org/10.1002/jpn3.70666
Primary Topic
Inflammatory Bowel Disease
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Pediatric inflammatory bowel diseases in patients with genetic syndromes: A case–control multicentre SIGENP study

Enrico Felici, Giacomo Colella, Matteo Bramuzzo, Francesco Graziano et al.
Journal of Pediatric Gastroenterology and Nutrition
Inflammatory Bowel Disease
article

Pediatric inflammatory bowel diseases in patients with genetic syndromes: A case–control multicentre SIGENP study

Enrico Felici, Giacomo Colella, Matteo Bramuzzo, Francesco Graziano, Francesca Di Sario, Chiara Monachesi, Maria Teresa Fioretti, Grazia Di Leo, Elvira Difrancisca, Francesca Penagini, Elena Lionetti, Licia Pensabene, Giulia D’Arcangelo, Simona Gatti, Serena Arrigo, Sara Curto, Massimo Martinelli, Giovanna Zuin, Flavio Labriola, Chiara Longo
article en

Abstract

OBJECTIVES: To characterize the clinical phenotype and long-term outcomes of pediatric inflammatory bowel disease (IBD) in patients with genetic syndromes. METHODS: Multicenter observational case-control study using data from the Italian Society of Pediatric Gastroenterology, Hepatology, and Nutrition IBD registry. Patients diagnosed with pediatric-onset IBD (<18 years) between 2009 and 2024 were included. Syndromic cases were matched 1:2 with non-syndromic controls by gender, age at diagnosis, IBD type, and follow-up duration. Demographic, clinical, and therapeutic data were analyzed. RESULTS: Sixty-nine patients were included (23 syndromic and 46 controls). At diagnosis, syndromic patients had lower weight (-1.16 z-score, p = 0.004) and height (-1.43 z-score, p < 0.001); these differences persisted at follow-up. Diagnostic delay was longer in syndromic patients (+6.5 months, p = 0.045). Abdominal pain was less frequent at presentation (p = 0.01). Syndromic patients had more hospitalizations (IBD-related incidence rate ratio [IRR] 1.23, p = 0.033; non-IBD IRR 1.65, p < 0.001), more comorbidities (odds ratio [OR] 18.2, p < 0.001), and greater use of non-IBD medications (OR 8.17, p = 0.004). The risk of additional autoimmune diseases was higher but not statistically significant. CONCLUSIONS: Pediatric IBD patients with genetic syndromes show impaired growth and delayed diagnosis, while intestinal disease activity and treatment exposure are comparable to non-syndromic peers. The higher burden of comorbidities and hospitalizations indicates greater healthcare complexity and diagnostic challenges; early recognition and coordinated multidisciplinary care are reasonable clinical considerations, but their impact on outcomes requires prospective evaluation.

Journal of Pediatric Gastroenterology and Nutrition
Marche Polytechnic University (IT), IRCCS Materno Infantile Burlo Garofolo (IT), Istituto Giannina Gaslini (IT), Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT), Magna Graecia University (IT), Ospedale Maggiore Carlo Alberto Pizzardi (IT), Ospedale Vincenzo Cervello (IT), Azienda di Rilievo Nazionale ed Alta Specializzazione (IT), ASST Fatebenefratelli Sacco (IT), Azienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare Arrigo (IT), University of Naples Federico II (IT)
Inflammatory Bowel Disease
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon